Hi. Good morning, everyone. Welcome to the next session at the UBS Global Biopharma Conference. I'm Alice Nettleton, one of the SMID Biotech Analysts at UBS. Happy to introduce Nektar Therapeutics. We have Jonathan Zalevsky, Chief Research and Development Officer. Welcome. Thank you so much for joining us.
Thank you for having us.
To start, would you like to give a brief overview of Nektar and, I guess, the positive data that you had this year in two indications for those who may be newer to the story, and then we can move to some Q&A?
Great. Thanks. Thank you, Alice, and thank you to the conference organizers for the invitation. At Nektar, we really focus on our core strength of understanding immunology and immune regulation, coupling that with our other core competency in polymer chemistry to put those two things together in what we hope is the most disruptive way. We used that foundation to invent a molecule called rezpegaldesleukin, which is the native IL-2 sequence, using our polymer chemistry technology, which together make it a regulatory T-cell selective agonist. This has allowed us to advance REZPEG in a range of different indications that are all really aligned with regulatory T-cell intervention. Very topical, as the Nobel Prize last year was given to the three people really sort of that characteristically discovered immune tolerance and discovered regulatory T-cells.
REZPEG was one of the molecules that was actually named by the Nobel Committee as being the most advanced asset that uses that as a therapeutic hypothesis and strategy towards intervention. With REZPEG, we have seen data in multiple phase II studies. As you mentioned, most recently, we saw evidence of really disruptive effect in patients with moderate-to-severe atopic dermatitis, and we also followed that up with activity in patients with severe-to-very severe alopecia areata. Very true to the promise of a regulatory T-cell-focused treatment, what we saw across those indications was this very profound durability of the effect. I think characteristic with many drugs that we take day-to-day, they are drugs that usually work, hopefully for us, but then the effect sort of erodes over time.
What we see consistently across multiple studies with REZPEG is a durability and even a deepening of effect that as patients take the drug longer and longer, their symptoms and the underlying pathology of the disease really seems to improve. We can withdraw the drug and see durability of effect off treatment, which is sort of, we think, a new paradigm shift, which can either lead to very infrequent dosing or substantial drug holidays. We are excited that all of this has come together in multiple phase III programs that we have now initiated. Three registrational studies in atopic dermatitis that have all kicked off this summer. Actually, next month, in December, we will kick off a registrational program in alopecia areata. A very exciting time for Nektar with the potential of bringing the first regulatory T-cell targeting drug into the clinic and into registration.
Great. Thank you. Maybe we can start with REZPEG in atopic derm. We have some off-treatment data coming up soon, I think, from that one, which people are focusing on. What would be a positive outcome here? What should investors expect?
Sure. Well, maybe I will just take a moment to sort of set the table, right? Early on in REZPEG's development, we did a small phase I trial where we treated people for 12 weeks, and then we took people off drug for 36 additional weeks. We saw not only maintenance, but even deepening of effect over the first few months. All the way out to that nine-month endpoint, we saw a very high sustainment of both the 75% improvement in EASI score, EASI75, and also in the vIGA-AD 0/1 response as well. When we designed the phase II, which was a much larger 400-patient trial, we prospectively built in this kind of observational off-drug period to really sort of characterize this phenomenon that we observed in the phase I trial.
In this phase II study, and the data that you mentioned coming in the first quarter for us early in 2027, we've now seen people that have been treated for 52 weeks. These are patients that were treated in the induction, people that reached an EASI50 or better advanced into maintenance, where they stayed on the same dose, either monthly or quarterly, through week 52. From week 52 onwards, now we have an off-drug observation for a year off treatment. We will have There are 125 patients that completed that maintenance period that moved into the 52-week observation. 15 of them were on placebo, and 110 were on REZPEG. The placebo was there that maintained the blind. This study was unique because the patient had no intervention.
This is different than traditional placebo withdrawal trials, like you see in the phase III programs of approved agents like lebrikizumab or DUPIXENT or NEMLUVIO even, where they had a randomized withdrawal to placebo and sham injection. Whereas in our study, there was no treatment at all, so people were just observed off drug. For us, this is going to be a very exciting patient population because this is really going to start to prospectively really characterize this off-treatment effect. What's the definition of success, right? Getting back to your original question. All of the relevant benchmark data really does come from these placebo withdrawal trials. We tend to focus on DUPIXENT because it is the most successful and the most heavily represented, and the greatest-selling example in the atopic dermatitis class.
In a nine-month placebo withdrawal, they showed about a 50% durability of EASI75 across that nine-month interval. If we see that level of efficacy at 12 months, and again, that's not a placebo withdrawal, there was still a sham injection with DUPIXENT, whereas we have no treatment at all. If we see that level of activity at 12 months, we think that's a bar of success. Obviously, if it's north of that's truly inspirational. Our goal with sort of how that data fits into the paradigm of REZPEG is that it doesn't necessarily say you've cured the disease. I think it's a little early to have a discussion like that, but it does tell us that very low-frequency dose regimens, whether they're once a quarter, maybe even twice a year, those are definitely possible for a mechanism like REZPEG.
Okay, that's helpful. How important is the off-treatment data that you just described to maybe improving REZPEG's profile or filling out REZPEG's profile and its potential in atopic derm when you speak to KOLs?
Yeah, we think that it really speaks to this differentiation of the mechanism, right? Because traditionally, really, most drugs are very symptom-controlling. They are mostly antagonists and inhibitors. They block a pathway. This pathway is elevated in disease, say IL-13, for example. If you are on target, you can get disease control, but when the drug washes out, the effect of the disease comes back, right? So, it is like lower durability kind of approaches. Whereas if you are getting truly disease modification, you are fixing the underlying pathology, which a Treg could do, that starts to really sort of branch out the opportunity and the benefit for the patient.
Okay. Now, you have initiated your full phase III program, I think, now for atopic derm with REZPEG, ZENITH-AD, three trials. Can you remind us of the design for each of those trials and when they are expected to read out?
Yeah, sure. All three trials will enroll about 510 patients, and AD1 is a trial that focuses on adolescent and up, so ages 12 and up. All patients will have moderate to severe atopic dermatitis, and these are patients that we call biologic-naive, so they have been untreated with a systemic, no JAK inhibitor, no biologic. So, this is the truly first-line population for whom topical steroids or TCIs are no longer suitable to control their disease. AD2, the second study, is also in adolescents ages 12 and up, also with moderate to severe atopic dermatitis, same kind of disease features. But this is a trial where REZPEG is given in combination with topical corticosteroid. This patient population is a blend of both biologic-naive and biologic-experienced patients that have had prior DUPIXENT, lebri, NEMLUVIO, Adbry, and/or a JAK inhibitor.
AD3, the third study, is also 510 patients, also adolescent, also moderate to severe atopic dermatitis, but this trial is a monotherapy study exclusively in the biologic and/or JAK-experienced population. So, these three trials, we think, give us a very kind of aggressive and differentiated labeling approach that is both possible nowadays, now that there are multiple entrants, but also really aligned with our mechanism and our aspirations to distinguish this mechanism of action from the existing drugs, which all primarily target the IL-4, IL-13 pathway. This will give us the opportunity to prospectively prove REZPEG's efficacy in the bio-experienced population, which gives second line very strong activity, but then also allows us to move into the first-line setting with AD1 and two, which address both the monotherapy and TCS combination.
We expect that the first study will read out around the summertime of 2028 with the top line from the induction. While we haven't guided specifically to the timing of AD2 and three, just based on how close in time they've all begun, they're all very coincident, and the rate of enrollment, we think all three studies will read out pretty close in time.
Okay, so it could all come in one release, or there'll be different releases, or you're not sure yet?
Yeah, or they'll come very close in time.
Okay.
Relative to each other. With the first one being the AD1 trial in naive.
ZENITH AD-1. That makes sense. On the bio-experienced versus bio-naive, there has been some debate around this limited evidence. I think the best evidence comes from the lebrikizumab trial. What are your current thoughts about what you can show in each setting?
Mm-hmm. Yeah. In these kind of chronic autoimmune inflammatory diseases, it is very common that, since it is a chronic treatment, patients continue therapy. It is different than oncology, where once you fail, you will never respond ever again, right, to that kind of chemo or other drug. If you take diseases like rheumatoid arthritis, right, it is common to cycle patients through these treatments. That study that you mentioned, the ADapt trial, with lebrikizumab, did sort of indicate that. It was an open-label study where patients had failed prior DUPIXENT, were treated with lebri, and they showed very similar response in an open-label cohort as lebri showed in their blinded phase III studies.
What we know from REZPEG is that our mechanism of action, being an agonist and not an antagonist, is really in no way, we believe, going to be hindered by a patient failing a prior IL-13 or IL-4 or IL-31 or even a JAK. In fact, we have shown very recently translational data that demonstrates that as early as week two after a single dose of REZPEG is already normalizing Th1, Th2, Th17, as well as fibrotic and other disease-associated pathways in atopic dermatitis patients based on proteomic and transcriptomic analysis of both skin and serum. So, we know that REZPEG can normalize the systemic immunology that it has, which we think gives us a really high opportunity to be efficacious in this patient population. That is why we designed AD-2 and AD-3 to include that population.
We feel very confident doing it this way and that REZPEG will be efficacious.
I want to touch on competition because I think this is on top of a lot of investors' minds, given the large number of bispecifics and even trispecifics in development. Can you talk about how REZPEG is obviously differentiated compared to these which rely on an IL-4, IL-13 backbone, but kind of how you see that landscape developing and how you can protect your position in the market?
Sure. I think that one thing that's really important is this is in a really large patient population. I mean, when you consider, say, psoriasis and atopic dermatitis, there's so many more atopic dermatitis patients, right? The opportunity to provide more treatment to more patients is even greater in this indication. We've seen as early as diseases like rheumatoid arthritis, again, that can have so many entrants come in and really expand this market. But if you consider what Centocor did at the time of launching Remicade, nobody thought this field would ever be as large, right, as it turned out to be today with Humira and all the entrants even after Humira. I do think that we're going to see this kind of theme sort of present itself over and over, and it'll be the case, I believe, in atopic dermatitis.
There's a lot of space. Why we're really keen on REZPEG, obviously, we're biased since we're Nektar, but even outside of that is that this really comes down to mechanism. These multispecifics, even these small molecules, are largely targeting the same pathways. They're important. They're providing, I think, better opportunities for patients, but they're still down the same treatment axis. We already know that you can only really get so far with targeting IL-4 and 13. There's plenty of patients that are not well served by those agents, whether they're intolerant due to conjunctivitis or other issues, or they just struggle to reach an EASI75 response. We think having more mechanisms of action is great for the field, and we think REZPEG is able to treat these additional patients that are not even going to be well served by the multispecifics.
Okay. That makes sense. Now, I want to talk about TNFR2. You have one or two preclinical TNFR2 assets, I believe, and there are a couple of other competitors out there. This is also a Treg approach, slightly different. I think it's supposed to enhance Treg function rather than Treg expansion, but perhaps you can explain a little bit more about that mechanism and give us an update on your assets.
Yeah. Thank you. TNFR2 is a TNF superfamily protein, right? When it signals, it signals through the NF-ĪŗB pathway, as opposed to REZPEG or IL-2, which signals through the JAK-STAT pathway. We know that more of like a growth factor for regulatory T cells is down the JAK-STAT pathway, and that's very traditionally what we know about IL-2 and the IL-2 receptor activation in regulatory T cells, where Tregs are priming, whether it's in the thymus or in the secondary lymphoid structures like a draining lymph node near a tissue. There's an ongoing proliferative effect. There's a need for what we call signal three, the cytokine, the IL-2, and that causes the expansion of the regulatory T cells. It's really in the setting of priming that we see the greatest activity of agonizing the IL-2 pathway.
When these Tregs, though, have proliferated and then they leave, whether the follicle or the thymus, they move into the blood and they egress into the different tissues. When they reach a tissue, that's where they have a number of sort of fate decisions to make, if you will, and they face a lot of cytokines that can be very harmful to their survival. That's where the NF-ĪŗB pathway and agonism through TNFR2 really comes into play. It sustains both the phenotype and then the functional status of those cells. Getting back to your original question, TNFR2 is not really a growth factor for Tregs. It's hard to proliferate and expand Tregs using TNFR2 agonism. You really have to change the biology of TNFR2 signaling in pretty dramatic ways if you want to try to make TNFR2 be a proliferator.
But what it does do is it stabilizes FOXP3 expression. It stabilizes the methylation status of the promoter, and it stabilizes that effector phenotype that Tregs have and need to maintain when they're using all of their regulatory properties in tissues. We think about the two molecules in our pipeline as sort of serving two different purposes. With REZPEG, it's like the true proliferator. It makes more Tregs than any TNFR2 agonist can make. The TNFR2 assets are important for maintaining the function of the Tregs and maintaining the drive of the regulatory mechanisms that they have in the tissue, and keeping that from basically being squelched by other practices. We're very aware that there are multiple assets now that are in development. I think there's a company called TRexBio that's in the clinic advancing a molecule in atopic dermatitis.
Yeah, definitely. I wanted to ask you about that next, actually. The TRexBio phase I-B readout in atopic derm that's expected in the first half of 2027. On one hand, this could be a competitor to REZPEG in AD and other indications, but it could also help to de-risk your own efforts with TNFR2. How are you thinking about this readout?
Yeah, I mean, first of all, we think all readouts are good and helpful for the field. This one or any other company or any other competitors, I think it's great, right? There's enough patients, and we all need to give as much medicine to patients as we can. So, we're very positive on all of those things. I think for them, it's an important step in their direction. I think that in our thought process, we had other indications that we thought were a little bit more relevant to this mechanism of action. But we're hopeful that the TNFR2 mechanism works in atopic derm. In terms of competition, REZPEG is so much further ahead.
So, all of these other molecules you asked about earlier, like bispecifics or some of the small molecules or the trispecifics, outside of Pfizer, that's just initiating phase III studies with their trispecific, all of the entire field is far behind, haven't even read out phase II. So, REZPEG is in a different sort of pole position relative to that other pipeline.
Okay. Maybe we can talk about REZPEG in alopecia next. So, you just mentioned you are starting the phase III very soon. Can you remind us of your current thoughts on the design of this trial, what you're looking to see? And I think you're doing a single trial, if I'm not mistaken.
Yeah, that's right. So, we're doing a single registrational study in about 850 patients. The patient population is, again, adolescent, ages 12 and up, and these are patients that have severe to very severe alopecia. So, they'd have a SALT score of 50 and higher as their inclusion criteria. One of the things that we saw in the phase II trial was that we saw the treatment through 52 weeks was profoundly important for the mechanism of REZPEG and for the success of the patient. In the phase II study, we had two treatment periods that we evaluated, and the 52-week treatment period really showed us the greatest elaboration of hair regrowth on the mechanism. Consequently, this phase III study is a 52-week treatment design, so where patients will get the 24 microgram per kilogram dose given twice a month over that 12-month or 52-week period.
Then we'll read out the primary endpoint, which is a proportion of patients that achieve a SALT 20 or better, as the key for induction. In phase II, we saw nearly 30% of patients could achieve that benchmark, which we were very excited about because it hit the low-dose JAK inhibitor kind of target, which is what we were hitting. It was even a little bit higher than low-dose Olumiant, which was our target goal in that phase II. So, we're very excited that REZPEG has the opportunity, being that we're initiating the phase III, to potentially be the first biologic that could reach approval in this patient population. Right now, we only have JAK inhibitors to treat the patients. With RINVOQ, the most recent entry coming in, that's great for patients, but it poses a lot of challenges for patients as well.
There's a tolerability challenge with treating with a JAK inhibitor for a long time. One of the biggest challenges is that when patients discontinue a JAK inhibitor, if they've gained hair regrowth, which is great, they'll really lose the hair that they regrew. There's a very, very low durability of that mechanism. We demonstrated in that phase II trial that patients that regrew hair, we followed for six months off drug after the end of treatment, and we saw 63% of people either keep any amount of hair that they regrew over that six-month period. But many people actually continued to grow hair, even in the six-month period off drug.
In fact, we saw that the SALT 10 proportion of patients tripled between the end of treatment and the six months off therapy treatment, really indicating, again, the unique difference of the REZPEG mechanism, the durability, and the sustained effect of REZPEG even after we stop treatment.
On the JAK inhibitor topic, AbbVie's RINVOQ could be approved, and that looks much more effective than the other JAK inhibitors. I understand the limitations of the JAK inhibitor class in this indication, but how do you think this might change the overall opportunity for REZPEG, and are you still planning to position this ahead of JAK inhibitors, or are you also considering post-JAK inhibitor experienced patients as well?
Yeah, I think RINVOQ is a very successful JAK inhibitor, and it tends to surpass all the other JAK inhibitors when it is tested in any kind of or it enters into any indication, has the most efficacy. It also has the most adversity as well, but it is sort of, it is like the JAK inhibitor of JAK inhibitors, if you will. So, it will do very well in the class against the other JAKs, but we think as a biologic, it really is going to be a limited kind of threat spectrum to REZPEG because the biologic offers a different opportunity, right, for the physician treating a chronic disease like alopecia areata. We have seen numerous examples where a JAK inhibitor and biologic are approved in the same indication, RA, atopic derm, and so on.
There is a very different usage of them because while JAK inhibitors are rapid with their efficacy, they are just difficult to give chronically, and many doctors are much more comfortable prescribing a biologic. So, we think it is important for alopecia and alopecia patients, but we actually do not think it is going to be a major impediment for REZPEG's opportunity.
Okay. Recently, you announced that you are going to look at vitiligo as another indication. Can you talk a little bit about your plans there, and when might we get data in this indication?
Sure, yeah. We just announced that on our earnings call last week. So, we have seen really a lot of activity in different kinds of dermal inflammatory and dermal immunology indications for REZPEG, and that includes patients with lupus that have cutaneous manifestations, patients with psoriasis, patients with atopic dermatitis, as we have discussed, and alopecia areata. The mechanism of how Tregs control the inflammation in the skin, particularly to the pigment-producing cells, is very similar to alopecia areata. The same kind of circuit that requires utilization of cytokines like interleukin-10, TGF-beta, which are missing in patients with vitiligo from the Treg axis, is exactly one of the ways that we think REZPEG can benefit these patients. So, we are going to kick off a small study. It would be roughly 30 patients that we will be kicking off very shortly.
The goal is to examine activity and assess the opportunity profile for REZPEG in vitiligo. Our goal is to have data from the study before the first of the phase III readouts in the summer of 2028. The goal is to have data before then.
Could that be the next catalyst after the off-treatment data in atopic derm then, before the phase III readouts in AD in 2028?
Yeah.
Okay.
It's a definite possibility.
Okay. Sounds good. Then just finishing up then, given the multiple phase III now underway and soon to initiate, you've got the vitiligo indication and also potential TNFR2 advancement at some point, how should we now think about R&D spend in the next couple of years? Just confirm if you're fully funded to reach those phase III atopic derm readouts in 2028.
Yeah, I mean, definitely we're very much in execution mode now, right? Besides the three registrational studies in atopic derm talked about, there's of course the alopecia registrational study. We expect that there will be increased focus and some uptick in the R&D spend to execute on those studies. But we just gave actually some guidance at earnings call last week. We're well-financed through the third quarter of 2028, well ahead the readouts of these registrational trials in atopic dermatitis.
Great. Well, I think we can leave it there, but thank you so much for joining us, and thank you everybody for being here.
Thank you, everyone.